06/09/2025
5:56 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/06/2025
3:15 PM | BIENAIME JEAN JACQUES (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2025
3:15 PM | GRAY MARY ANN (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2025
3:15 PM | Keros Therapeutics (Issuer)
Seth Alpna (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2025
3:15 PM | Keros Therapeutics (Issuer)
Nussbaum Ran (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2025
3:15 PM | Kariv Tomer (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2025
3:15 PM | Farzan Nima (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2025
3:15 PM | GORDON CARL L (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2025
3:15 PM | Keros Therapeutics (Issuer)
Knowles Julius (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/29/2025
5:58 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/27/2025
12:49 PM | Keros Therapeutics (Filer)
| Form DEFA14A | |
Get the Latest News and Ratings for KROS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
05/19/2025
7:00 AM | Keros Therapeutics (Filer)
| Form DEFA14A | |
05/19/2025
7:01 AM | Keros Therapeutics (Filer)
| Form DEFA14A | |
05/19/2025
7:02 AM | Keros Therapeutics (Filer)
| Form DEFA14A | |
05/14/2025
4:49 PM | Keros Therapeutics (Subject)
Madison Avenue Partners, LP (Filed by)
| Form SCHEDULE 13G | |
05/12/2025
10:29 AM | ADAR1 Capital Management, LLC (Filed by)
Keros Therapeutics (Subject)
| Form SCHEDULE 13D/A | |
05/12/2025
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/05/2025
1:03 PM | JPMORGAN CHASE & CO (Filed by)
JPMORGAN CHASE & CO (Filed by)
Keros Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
05/02/2025
8:59 AM | JPMORGAN CHASE & CO (Filed by)
JPMORGAN CHASE & CO (Filed by)
Keros Therapeutics (Subject)
| Form SCHEDULE 13G | |
04/30/2025
10:23 AM | Keros Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SCHEDULE 13G | |
04/28/2025
5:43 PM | ADAR1 Capital Management, LLC (Filed by)
Keros Therapeutics (Subject)
| Form SCHEDULE 13D/A | |
04/23/2025
3:09 PM | Keros Therapeutics (Filer)
| Form ARS | |
04/23/2025
3:03 PM | Keros Therapeutics (Filer)
| Form DEF 14A | |
04/11/2025
8:57 PM | ADAR1 Capital Management GP, LLC (Reporting)
ADAR1 Capital Management, LLC (Reporting)
ADAR1 Partners, LP (Reporting)
Keros Therapeutics (Issuer)
Schneeberger Daniel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/11/2025
7:58 PM | ADAR1 Capital Management GP, LLC (Reporting)
ADAR1 Capital Management, LLC (Reporting)
ADAR1 Partners, LP (Reporting)
Keros Therapeutics (Issuer)
Schneeberger Daniel (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
04/11/2025
7:32 PM | ADAR1 Capital Management, LLC (Filed by)
Keros Therapeutics (Subject)
| Form SCHEDULE 13D | |
04/10/2025
5:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/10/2025
5:04 AM | Keros Therapeutics (Filer)
| Form 8-A12B | |
04/07/2025
3:15 PM | Keros Therapeutics (Issuer)
Seehra Jasbir (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/31/2025
5:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/28/2025
4:01 PM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/07/2025
9:23 AM | FMR LLC (Filed by)
Keros Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
01/30/2025
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/24/2025
3:15 PM | Keros Therapeutics (Issuer)
Regnante Keith (Reporting)
| Form 4/A | |
01/21/2025
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/15/2025
5:31 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/10/2025
7:00 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/12/2024
5:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/03/2024
6:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/26/2024
7:02 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/08/2024
3:18 PM | CHYUNG YUNG H. (Reporting)
Keros Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
Why July 22nd Could Mean Big Changes for Social Security (Ad) In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Social Security — and his plan is set to roll out July 22.
What's coming next isn't about trimming waste. To see the full playbook and how it could impact everyone, click here. |
11/06/2024
3:22 PM | Keros Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/06/2024
7:02 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/16/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/30/2024
7:00 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/03/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/28/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/15/2024
4:06 PM | GORDON CARL L (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
4:01 PM | Keros Therapeutics (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VII LLC (Reporting)
OrbiMed Genesis GP LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/13/2024
3:12 PM | Keros Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/07/2024
3:02 PM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
4:15 PM | Keros Therapeutics (Filer)
| Form 424B5 | |
06/17/2024
4:17 PM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
5:07 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
